Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Accumulated Expenses (2019 - 2025)

Bioadaptives' Accumulated Expenses history spans 7 years, with the latest figure at $203997.0 for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 18.94% year-over-year to $203997.0; the TTM value through Sep 2025 reached $203997.0, up 18.94%, while the annual FY2024 figure was $171507.0, 24.32% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $203997.0 at Bioadaptives, up from $190167.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $203997.0 in Q3 2025 and bottomed at $1019.0 in Q1 2023.
  • The 5-year median for Accumulated Expenses is $113606.5 (2022), against an average of $89792.4.
  • The largest annual shift saw Accumulated Expenses plummeted 85.67% in 2021 before it skyrocketed 14223.16% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $6200.0 in 2021, then skyrocketed by 1527.73% to $100919.0 in 2022, then skyrocketed by 36.7% to $137955.0 in 2023, then increased by 24.32% to $171507.0 in 2024, then increased by 18.94% to $203997.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Accumulated Expenses are $203997.0 (Q3 2025), $190167.0 (Q2 2025), and $180837.0 (Q1 2025).